Why in news?
- The Institute of Life Sciences (ILS), under the Department of Biotechnology successfully developed antibodies against the Chikungunya viral (CHIKV) infection.
More in news
- ILS research lab became the first to develop polyclonal antibodies against the non-structural proteins – nsP1, nsP3 and nsP4 of CHIKV.
- The Lab also developed and characterized a monoclonal antibody against nsP2 of CHIKV
- Now that the antibodies have successfully been tested ILS has got non-exclusive license for commercialisation of the product.
- ILS is to partner with a biotechnology-based company for product commercialisation and marketing of antibodies
Significance of Developing Antibodies
- It will help researchers unravel countless aspects of virus pathogenesis
- With this development researchers can make progress towards creation of efficacious antivirals and other control strategies against the Chikungunya virus.
Source
The Hindu